$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000147929015000010 Filed on November 10, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$75.00K	$75.00K	$75.00K
YoY Change	0.0%	0.0%	-52.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.910M	$5.827M	$5.300M
YoY Change	44.26%	9.94%	147.43%
% of Gross Profit
Research & Development	$14.96M	$13.02M	$8.600M
YoY Change	63.86%	51.35%	36.86%
% of Gross Profit
Depreciation & Amortization	$410.0K	$510.0K	$600.0K
YoY Change	-16.33%	-15.0%	50.0%
% of Gross Profit
Operating Expenses	$21.86M	$18.84M	$13.90M
YoY Change	57.04%	35.56%	64.97%
Operating Profit		-$18.77M	-$13.83M
YoY Change		35.75%	67.21%
Interest Expense	-$200.0K	$390.0K	$228.0K
YoY Change	0.0%	71.05%	-35.04%
% of Operating Profit
Other Income/Expense, Net	-$110.0K	-$98.00K	-$5.000K
YoY Change	-31.25%	1860.0%	-86.84%
Pretax Income	-$22.09M	-$19.18M	-$13.98M
YoY Change	55.45%	37.2%	57.43%
Income Tax
% Of Pretax Income
Net Earnings	-$22.09M	-$19.18M	-$13.98M
YoY Change	55.46%	37.19%	57.42%
Net Earnings / Revenue	-29458.67%	-25566.67%	-18636.0%
Basic Earnings Per Share	-$0.83	-$0.81	-$0.60
Diluted Earnings Per Share	-$0.83	-$0.81	-$0.60
COMMON SHARES
Basic Shares Outstanding	28.06M shares	23.76M shares	23.33M shares
Diluted Shares Outstanding		23.76M shares	23.33M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$252.3M	$141.9M	$187.5M
YoY Change	47.54%	-24.32%	9768.42%
Cash & Equivalents	$201.6M	$90.49M	$187.5M
Short-Term Investments	$50.70M	$51.40M
Other Short-Term Assets	$267.0K	$1.600M	$86.00K
YoY Change	11.72%	1760.47%	-92.18%
Inventory
Prepaid Expenses	$1.200M		$1.451M
Receivables	$75.00K		$1.421M
Other Receivables	$83.00K		$0.00
Total Short-Term Assets	$254.0M	$143.5M	$190.9M
YoY Change	47.03%	-24.84%	6263.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.71M	$19.25M	$17.39M
YoY Change	2.25%	10.69%	32.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.800M	$2.400M
YoY Change
Other Assets	$0.00	$6.000K	$183.0K
YoY Change	-100.0%	-96.72%	-93.46%
Total Long-Term Assets	$21.86M	$22.02M	$18.01M
YoY Change	10.75%	22.24%	13.28%
TOTAL ASSETS
Total Short-Term Assets	$254.0M	$143.5M	$190.9M
Total Long-Term Assets	$21.86M	$22.02M	$18.01M
Total Assets	$275.8M	$165.5M	$208.9M
YoY Change	43.31%	-20.78%	1005.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.657M	$2.731M	$2.666M
YoY Change	-15.62%	2.44%	-73.6%
Accrued Expenses	$6.245M	$5.990M	$3.317M
YoY Change	50.66%	80.58%	-32.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.100M	$3.000M	$8.800M
YoY Change	6.9%	-65.91%	6.02%
Total Short-Term Liabilities	$12.04M	$11.74M	$14.75M
YoY Change	17.59%	-20.4%	-53.48%
LONG-TERM LIABILITIES
Long-Term Debt	$5.300M	$6.200M	$900.0K
YoY Change	783.33%	588.89%	-85.71%
Other Long-Term Liabilities	$0.00	$5.200M	$5.300M
YoY Change	-100.0%	-1.89%	12.77%
Total Long-Term Liabilities	$0.00	$11.40M	$6.200M
YoY Change	-100.0%	83.87%	-43.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.04M	$11.74M	$14.75M
Total Long-Term Liabilities	$0.00	$11.40M	$6.200M
Total Liabilities	$22.57M	$23.16M	$21.01M
YoY Change	40.19%	10.23%	-50.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$332.3M	-$310.2M	-$244.6M
YoY Change	28.39%	26.82%
Common Stock	$585.6M	$452.5M	$432.5M
YoY Change	34.56%	4.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$253.3M	$142.4M	$187.9M
YoY Change
Total Liabilities & Shareholders Equity	$275.8M	$165.5M	$208.9M
YoY Change	43.31%	-20.78%	1005.41%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$22.09M	-$19.18M	-$13.98M
YoY Change	55.46%	37.19%	57.42%
Depreciation, Depletion And Amortization	$410.0K	$510.0K	$600.0K
YoY Change	-16.33%	-15.0%	50.0%
Cash From Operating Activities	-$16.45M	-$13.71M	-$12.69M
YoY Change	80.37%	8.04%	96.14%
INVESTING ACTIVITIES
Capital Expenditures	-$480.0K	-$560.0K	-$2.020M
YoY Change	-68.83%	-72.28%	477.14%
Acquisitions
YoY Change
Other Investing Activities	$920.0K	-$1.010M	$0.00
YoY Change
Cash From Investing Activities	$440.0K	-$1.570M	-$2.030M
YoY Change	-127.33%	-22.66%	463.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	127.1M	9.350M	-1.110M
YoY Change	-2290.52%	-942.34%	-49.32%
NET CHANGE
Cash From Operating Activities	-16.45M	-13.71M	-12.69M
Cash From Investing Activities	440.0K	-1.570M	-2.030M
Cash From Financing Activities	127.1M	9.350M	-1.110M
Net Change In Cash	111.0M	-5.930M	-15.83M
YoY Change	-771.75%	-62.54%	75.5%
FREE CASH FLOW
Cash From Operating Activities	-$16.45M	-$13.71M	-$12.69M
Capital Expenditures	-$480.0K	-$560.0K	-$2.020M
Free Cash Flow	-$15.97M	-$13.15M	-$10.67M
YoY Change	110.69%	23.24%	74.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28062233	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2015Q3	rvnc	Cash Cash Equivalentsand Investments CashCashEquivalentsandInvestments	144200000	USD
	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2014Q3	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	-210000	USD
CY2015Q3	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	1441000	USD
	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	0	USD
	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	1356000	USD
	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	0	USD
CY2014Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	598000	USD
CY2015Q3	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	6176000	USD
CY2014Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	307000	USD
CY2015Q3	rvnc	Financing Obligation Current FinancingObligationCurrent	3018000	USD
CY2015Q3	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	10191000	USD
CY2015Q3	rvnc	Financing Obligation Future Minimum Payments Duein Four Years FinancingObligationFutureMinimumPaymentsDueinFourYears	949000	USD
CY2015Q3	rvnc	Financing Obligation Future Minimum Payments Duein Three Years FinancingObligationFutureMinimumPaymentsDueinThreeYears	3971000	USD
CY2015Q3	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	4217000	USD
CY2015Q3	rvnc	Financing Obligation Future Minimum Payments Next Twelve Months FinancingObligationFutureMinimumPaymentsNextTwelveMonths	1054000	USD
CY2014Q3	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	0	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	39000	USD
	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	-1356000	USD
CY2015Q3	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2014Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	67000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-426000	USD
CY2015Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	13000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	60000	USD
CY2014Q3	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	238000	USD
	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	649000	USD
CY2015Q3	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
CY2014Q3	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	1250000	USD
CY2015Q3	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
CY2014Q3	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	48000	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	148000	USD
CY2015Q3	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
CY2014Q3	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	76000	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	219000	USD
CY2015Q3	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	5000	USD
	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	6490000	USD
	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	0	USD
	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	981000	USD
	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	0	USD
	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	80000	USD
CY2015Q3	rvnc	Maximum Commission Basedon Gross Salesof Secondary Offering MaximumCommissionBasedonGrossSalesofSecondaryOffering	0.03
	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	4574000	USD
	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	84000	USD
CY2014Q3	rvnc	Noncash Interest Expense NoncashInterestExpense	-48000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	9365000	USD
CY2015Q3	rvnc	Noncash Interest Expense NoncashInterestExpense	126000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	270000	USD
	rvnc	Proceeds From Issuanceof Follow On Offering ProceedsFromIssuanceofFollowOnOffering	131882000	USD
	rvnc	Proceeds From Issuanceof Follow On Offering ProceedsFromIssuanceofFollowOnOffering	0	USD
CY2015Q1	rvnc	Proceedsfrom Issuanceof Common Stock Maximum Proceeds Allowedon Secondary Offering ProceedsfromIssuanceofCommonStockMaximumProceedsAllowedonSecondaryOffering	50000000	USD
	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	210000	USD
	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	0	USD
	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	58000	USD
	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	0	USD
CY2015Q3	rvnc	Working Capital Surplus WorkingCapitalSurplus	131800000	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	0	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	28000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3149000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2731000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-364000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4145000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5990000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	435142000	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	452501000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2285000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4611000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2590000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7314000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1198000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	148000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	39000	USD
CY2014Q4	us-gaap	Assets Assets	192469000	USD
CY2015Q3	us-gaap	Assets Assets	165514000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	172731000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	143497000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	166038000	USD
CY2015Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	126175000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	166038000	USD
CY2015Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	126165000	USD
CY2014Q3	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2015Q3	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	22000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	10000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3914000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187486000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171032000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90494000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	183572000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-80538000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23774465	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24313222	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23774465	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24313222	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13977000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48705000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19153000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51372000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	123982000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1095000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	26206000	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3725000	USD
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3762000	USD
	us-gaap	Depreciation Depreciation	1561000	USD
	us-gaap	Depreciation Depreciation	1586000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1541000	USD
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1481000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.70
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.70
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	144000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	226000	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2151000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	66000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	66000	USD
CY2015Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	126000	USD
CY2014Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	4032000	USD
CY2015Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8331000	USD
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3524000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-477000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1178000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3096000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-83000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-7073000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1238000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-24000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2654000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	134000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-500000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-152000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	228000	USD
	us-gaap	Interest Expense InterestExpense	10336000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	390000	USD
	us-gaap	Interest Expense InterestExpense	834000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	271000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2014Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	276000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	971000	USD
CY2015Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	264000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	564000	USD
	us-gaap	Interest Paid InterestPaid	971000	USD
	us-gaap	Interest Paid InterestPaid	564000	USD
CY2014Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	14000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	18000	USD
CY2015Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	68000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2014Q4	us-gaap	Liabilities Liabilities	16100000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	23158000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192469000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165514000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10236000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11739000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2015Q3	us-gaap	Long Term Investments LongTermInvestments	2357000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	234892000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15541000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5369000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56861000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45951000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39218000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-13977000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48705000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-19175000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-51382000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13977000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48705000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19175000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-51382000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13977000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-48705000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19175000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-51382000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	832000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	95000	USD
	us-gaap	Notes Assumed1 NotesAssumed1	1050000	USD
	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2635000	USD
CY2015Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	13900000	USD
	us-gaap	Operating Expenses OperatingExpenses	38511000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	18843000	USD
	us-gaap	Operating Expenses OperatingExpenses	50756000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13825000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38203000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18768000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50531000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	49817000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1269000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5578000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5394000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5222000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	32354000	USD
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3900000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	10000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3900000	USD
	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-73000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-98000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-221000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1438000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	762000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	54087000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5444000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2849000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1624000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1604000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	102672000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10154000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6750000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1402000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	738000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19274000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19254000	USD
CY2015Q3	us-gaap	Purchase Obligation PurchaseObligation	22400000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	146000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1768000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6230000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2652000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8600000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24261000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13016000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32573000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	35000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	435000	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-258797000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-310179000	USD
CY2014Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	308000	USD
CY2015Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	225000	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	0	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	9831000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5300000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14250000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5827000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18183000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4611000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7314000	USD
CY2013Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	2500000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2015Q3	us-gaap	Short Term Investments ShortTermInvestments	51364000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	176369000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	142356000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23331104	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18009537	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23755199	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23625869	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23331104	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18009537	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23755199	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23625869	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a settlement and termination agreement with Medicis Pharmaceutical Corporation, or Medicis. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and the remaining </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT001 or RT002 by the Company, or Product Approval Payment. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.75</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.09%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">7.25%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2019. The Company did not make any payments under the Product Approval Payment during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates</font></div></div>

Files In Submission

Name	View Source	Status
0001479290-15-000010-index-headers.html	Edgar Link	pending
0001479290-15-000010-index.html	Edgar Link	pending
0001479290-15-000010.txt	Edgar Link	pending
0001479290-15-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20150930.xml	Edgar Link	completed
rvnc-20150930.xsd	Edgar Link	pending
rvnc-20150930_cal.xml	Edgar Link	unprocessable
rvnc-20150930_def.xml	Edgar Link	unprocessable
rvnc-20150930_lab.xml	Edgar Link	unprocessable
rvnc-20150930_pre.xml	Edgar Link	unprocessable
rvnc-q315exhibit101.htm	Edgar Link	pending
rvnc-q315exhibit102.htm	Edgar Link	pending
rvnc-q315exhibit103.htm	Edgar Link	pending
rvnc-q315exhibit104.htm	Edgar Link	pending
rvnc-q315exhibit105.htm	Edgar Link	pending
rvnc-q315exhibit106.htm	Edgar Link	pending
rvnc-q315exhibit311.htm	Edgar Link	pending
rvnc-q315exhibit312.htm	Edgar Link	pending
rvnc-q315exhibit321.htm	Edgar Link	pending
rvnc-q315exhibit322.htm	Edgar Link	pending
rvncq31510q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2015 Q4 Form 10-Q Financial Statement

#000147929015000010 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2015 Q4 Form 10-Q Financial Statement

#000147929015000010 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc